Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arcturus Therapeutics Holdings Inc ARCT

Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc. is a global messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid... see more

Recent & Breaking News (NDAQ:ARCT)

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

Business Wire January 24, 2022

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 21, 2022

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors

GlobeNewswire January 18, 2022

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 17, 2021

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

Business Wire December 16, 2021

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

Business Wire December 13, 2021

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

Business Wire November 22, 2021

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 18, 2021

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

Business Wire November 8, 2021

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

Business Wire October 25, 2021

Arcturus Therapeutics Announces Leadership Appointments

Business Wire October 21, 2021

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 20, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR(TM) mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Business Wire October 12, 2021

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Business Wire September 22, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR(TM) mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Business Wire September 22, 2021

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Business Wire September 8, 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Business Wire September 7, 2021

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

Business Wire August 9, 2021

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR(TM) mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

Business Wire August 3, 2021

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR(TM) mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

Business Wire August 2, 2021